Related Experiment Video

Updated: Aug 29, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Medrogestone and an LHRH analogue as potential combination therapy for hormone-dependent cancers

C Auclair, M L Givner

    Archives of Andrology
    |February 1, 1982
    PubMed

    Insights

    Medrogestone and an LHRH agonist both reduced prostate size in rats. Combining these treatments for prostate cancer therapy significantly decreased ventral prostate weight.

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Urology

    Background:

    • Prostate cancer is a significant health concern.
    • Hormonal therapies are crucial for managing hormone-dependent cancers.
    • Understanding the effects of progestational and antiandrogenic compounds on the prostate is important.

    Purpose of the Study:

    • To investigate the effects of medrogestone, a progestational and antiandrogenic compound, on rat prostate.
    • To evaluate the impact of a potent LHRH agonist on rat prostate and reproductive parameters.
    • To assess the combined efficacy of medrogestone and LHRH agonist in reducing prostate weight.

    Main Methods:

    • Adult male rats were treated with medrogestone (5 mg/kg s.c. for 1-4 weeks).
    • Rats received a potent LHRH agonist (500 ng s.c. for 2-4 weeks).
    • A combination therapy group was treated for 4 weeks.

    Main Results:

    • Medrogestone alone caused ventral prostate atrophy without affecting testicular parameters or testosterone.
    • LHRH agonist suppressed testicular weight, LH/hCG receptor levels, and plasma testosterone, causing seminal vesicle and prostate atrophy.
    • Combined treatment resulted in the most significant decrease in prostatic weight.

    Conclusions:

    • Medrogestone exhibits antiandrogenic properties affecting the prostate.
    • LHRH agonists have a systemic suppressive effect on the reproductive axis and prostate.
    • Combination therapy with medrogestone and LHRH agonist shows potential for treating hormone-dependent cancers due to enhanced prostatic atrophy.

    More Related Videos

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

    Published on: August 13, 2019

    Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives08:46

    Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

    Published on: September 16, 2021

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Transducer Mechanism: Nuclear Receptors01:31

    Transducer Mechanism: Nuclear Receptors

    Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
    About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
    Target Cell Response to Hormones01:22

    Target Cell Response to Hormones

    Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
    Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Hormonal Regulation of the Menstrual Cycle01:22

    Hormonal Regulation of the Menstrual Cycle

    The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
    At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
    Intrauterine Drug Delivery Systems01:21

    Intrauterine Drug Delivery Systems

    Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...